Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab - Wikidata - wikimedia - TriplyDB

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

http://www.wikidata.org/entity/Q24816557

about

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?Q24816951 Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.Update on the treatment of ankylosing spondylitis.Spondyloarthritides: evolving therapies Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.ASAS/EULAR recommendations for the management of ankylosing spondylitis.Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis.Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research.Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?Management and evaluation of extra-articular manifestations in spondyloarthritis Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.TNFalpha blockade in human diseases: an overview of efficacy and safety.Economic considerations of the treatment of ankylosing spondylitis.Tumour necrosis factor inhibitors in ankylosing spondylitis.Medical Treatment of Ankylosing Spondylitis Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis.Developments in the scientific and clinical understanding of the spondyloarthritides Infliximab in the treatment of ankylosing spondylitis.Long-term use of adalimumab in the treatment of rheumatic diseases.A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.Inflammatory arthritis: an overview for primary care physicians.Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?Biologic therapies for spondyloarthritis: what is new?

P2860

Q21195369-0FC1BF27-7511-4269-BA51-68F38AAED12B Q24816905-119DD08E-F83C-4742-B7FE-633646CEADE4 Q24816951-B7FDD288-B377-42CE-9E1F-F52B336E8FA4 Q26774173-55F0C5FC-6331-487A-80E9-669BF7D88FFA Q26852081-4CDB1468-F784-4B18-BACE-E17E7ED11399 Q33766318-81C701A0-71C3-4BEB-A7DF-CF8458587485 Q34449888-C42AED16-2172-4B52-9FDC-6DA2AE106A90 Q34592673-26465DBF-449E-4303-9DDB-EC6A04BF9C30 Q34613907-8F2AEE9E-7B69-4C06-B144-067CFCF075EC Q34894874-C1706628-8F78-49CB-8D74-DB3C1EF03CE3 Q34941693-C5CF0EAB-74E1-4FA8-8AB5-AA457E4A8069 Q35579517-53EAD7BC-1A38-4512-98D2-32C0E6974E83 Q35636900-997BAFF9-C59E-4AC5-B0F0-2567ABB38D0D Q35637012-7348FA55-D1F3-4CA8-BA74-EEE6646C01B6 Q35687019-883C8F8C-A4B5-4BFF-AC80-DB9D74C0F8C9 Q35953401-ABAE7114-C773-4EB7-A226-7EAD4D463E81 Q35986462-36F67E81-912C-4EA2-A8B1-8271ADDC3A4F Q35996265-854AFB87-2BD0-4B97-B255-C16607FBAB37 Q36059338-19BEA408-9119-4617-8391-143E6F5A39FE Q36292652-CD9DF9B8-C86F-4A33-BBDC-49C80C730D65 Q36439889-9B090AAE-A89A-45AD-AC19-7AAD14CDE540 Q36458447-B5A819B8-9D13-452C-9EC0-7D711D7DEB18 Q36536861-ACB70B68-2ECF-4399-8692-7BFB44079DB9 Q36731613-79A43AAE-C6E0-484F-8E73-A047A2B51866 Q37142118-91ACEABD-1C69-45F9-AD3D-96A27129FA2F Q37147133-5AC85EAC-1757-4ACB-B4EC-85B46D8B8092 Q37184062-6ADD4A22-38F2-4D3F-9C46-1C6DC4D88E3A Q37207018-7EFDAAC7-8989-4484-9B48-30D1ADA68D6C Q37290474-A39109B4-7053-410A-B26D-D27BBA051A43 Q37358124-B572AD44-A920-4DDA-B20B-712D60F93C37 Q37369583-C330C0FD-55ED-4F6E-9490-04FE25679ED0 Q37427257-6DD5DFF3-DD7D-4E7C-85FD-8176B4E94519 Q37465472-6D2868E7-A547-4599-90AE-34FA502C0195 Q37465518-0DCEA9AF-E611-480F-805B-8698A44551D9 Q37473648-23B34910-31EF-4E3E-BC6A-78A70FF9DBCF Q37729028-155E5786-FEED-4287-BB82-B62E90AC8571 Q37882064-7EEEC882-9229-41CB-A8E9-218FD75A8622 Q37994661-70C6B521-A753-4FF1-9D84-91F20C45FA9F Q38007111-81E25347-948B-4EDE-9155-37EC3BB7518C Q38031436-887BBCE5-57C5-4EE4-8E41-727120F36DD1

P2860

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

http://www.wikidata.org/entity/Q24816557

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Clinical response to discontin ...... uous treatment with infliximab

@ast

Clinical response to discontin ...... uous treatment with infliximab

@en

Clinical response to discontin ...... uous treatment with infliximab

@nl

type

label

Clinical response to discontin ...... uous treatment with infliximab

@ast

Clinical response to discontin ...... uous treatment with infliximab

@en

Clinical response to discontin ...... uous treatment with infliximab

@nl

prefLabel

Clinical response to discontin ...... uous treatment with infliximab

@ast

Clinical response to discontin ...... uous treatment with infliximab

@en

Clinical response to discontin ...... uous treatment with infliximab

@nl

P1433

Q24816557-D781EC03-0E4B-4A72-815C-1318E2E83376

P1476

Q24816557-E1AE04E9-A27A-48C5-9B04-6C705E74BC1F

P2093

Q24816557-08EBAEA6-9079-4673-9828-6AF9799BBE1B

Q24816557-279B13F3-2DD7-4328-8BFE-5F859AE09360

Q24816557-3BA8DCC8-C5BA-4EC7-B5D3-DC9CDE35B932

Q24816557-40A694E3-34D0-49B0-9623-AB61B769D775

Q24816557-4A779AA6-5B54-46AC-9935-FB6FB22CD469

Q24816557-4B6562C9-8E2C-461A-A183-30E012C9AA63

Q24816557-6C49689F-B326-460A-AB2C-6E6454A3E1C8

Q24816557-7019985E-E0CD-4C87-AEE7-E215FC774B05

Q24816557-931E0A65-B8E5-4460-A19A-E12F9009942F

Q24816557-AE0B9EF0-5A56-4586-9C01-F0EB09E8DD70

P2860

Q24816557-04563A86-86BB-4FAD-9408-66AE67B10340

Q24816557-0FF176E0-3107-447B-A932-E149497EFD2A

Q24816557-3454831E-4873-4301-B158-46EB9CC158E5

Q24816557-8CACEED0-F02B-436F-AA99-5D293DF8AA9B

Q24816557-9E45260D-B3D0-4216-BF3A-CA9381C67F50

Q24816557-A4395451-F436-4CB2-9ED6-438A6668A8ED

Q24816557-A55041C9-D967-4A7D-9B5B-EC8129A772E5

Q24816557-CB219D21-978D-4A02-BA85-541F397D650D

Q24816557-DB659656-3BB3-4E79-8D54-23A35F88028F

Q24816557-E5B704F9-9A5B-4999-88A6-1AFDE28E9AA4

P2888

Q24816557-EC70346A-3D8B-4CF3-90A5-43AE3948E440

P304

Q24816557-A826E92E-08DD-4C15-819B-EB1875D61FDE

P31

Q24816557-A59FAFB5-6576-43DF-93CC-1D29FB725CA0

P3181

Q24816557-C8E7C8FE-8DF7-43C9-A5DB-4477A1C5EBA2

P356

Q24816557-40441089-A530-4545-896A-A1F236CB266F

P407

Q24816557-6494E4AF-4576-44A9-90D9-702B9BBF8C23

P433

Q24816557-60386656-D826-46D0-9A0E-5AA8C6F20DF0

P478

Q24816557-2550258C-62B4-497B-80CD-148689944D68

P577

Q24816557-57944DB7-F664-462C-88B5-B86920D29E94

P5875

Q24816557-480E796A-7DF4-4716-A947-4A4FC3B10A5A

P6179

Q24816557-E2B8A938-7678-4A76-921F-FDE404EB10BC

P698

Q24816557-3C90B205-996B-4F28-A62D-69F25593D25B

P921

Q24816557-5E034FA7-DEA9-457A-B52B-DAE0E81A9D09

Q24816557-FB307D46-19D8-48A0-83EB-E524D3E0904A

P932

Q24816557-36693902-8F8F-4F6A-8FE1-FF434D5E65CC

P3181

P356

P1433

Arthritis Research and Therapy

P1476

Clinical response to discontin ...... uous treatment with infliximab

@en

P2093

Angela Zink

http://www.w3.org/2001/XMLSchema#string

Erika Gromnica-Ihle

http://www.w3.org/2001/XMLSchema#string

Gerd Burmester

http://www.w3.org/2001/XMLSchema#string

Helmut Sörensen

http://www.w3.org/2001/XMLSchema#string

Henning Zeidler

http://www.w3.org/2001/XMLSchema#string

Herbert Kellner

http://www.w3.org/2001/XMLSchema#string

Jan Brandt

http://www.w3.org/2001/XMLSchema#string

Joachim Listing

http://www.w3.org/2001/XMLSchema#string

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

Juergen Braun

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.

The sacroiliac joint in the spondyloarthropathies.

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.

Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

P2888

P304

R439-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1519263

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/AR1693

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7842569

http://www.w3.org/2001/XMLSchema#string

P6179

1010888988

http://www.w3.org/2001/XMLSchema#string

P698

15899030

http://www.w3.org/2001/XMLSchema#string

P921

P932

1174938

http://www.w3.org/2001/XMLSchema#string